Tibotec Pharmaceuticals to present HIV trial data at EACS
Two Phase 3 clinical Echo and Thrive trials evaluated the efficacy and safety of rilpivirine in 1,368 antiretroviral treatment-naïve HIV-1-infected adults. The 96 week trial demonstrated that rilpivirine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.